Trial Profile
To assess effectiveness of Mepolizumab on phenotypic characteristics of Asthmatic patients who failed to respond to omalizumab.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Mar 2018
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 23 Mar 2018 New trial record
- 05 Mar 2018 Results presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology